| Identification | Back Directory | [Name]
MBM-17 | [CAS]
2083621-90-1 | [Synonyms]
MBM-17
MBM 17,MBM17
Benzamide, 4-[7-[1-[2-(dimethylamino)ethyl]-1H-pyrazol-4-yl]imidazo[1,2-a]pyridin-3-yl]-2-(phenylmethoxy)- | [Molecular Formula]
C28H28N6O2 | [MDL Number]
MFCD32174238 | [MOL File]
2083621-90-1.mol | [Molecular Weight]
480.56 |
| Chemical Properties | Back Directory | [density ]
1.26±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
15.43±0.50(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
MBM-17 is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC50 of 3 nM. It effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55 shows antitumor activities, and no obvious toxicity to mice[1]. | [in vivo]
MBM-17 (20 mg/kg; i.p.; twice a day for 21 days) exhibits good antitumor activity and a well-tolerated dose schedule[1].
MBM-17 (1.0 mg/kg; i.v.) treatment shows CL, Vss, T1/2, AUC0-t, and AUC0-∞ values of 42.4 mL/min/kg, 4.06 L/kg, 2.42 hours, 386 ng/h/mL, and 405 ng/h/mL, respectively[1]. | Animal Model: | Female BALB/c nu/nu mice (5-6 weeks, bearing HCT-116 xenografts)[1] | | Dosage: | 20 mg/kg | | Administration: | Intraperitoneal injection; twice a day for 21 days | | Result: | Tmor growth was significantly suppressed.
|
| Animal Model: | Male Sprague Dawley (SD) rats[1] | | Dosage: | 1.0 mg/kg | | Administration: | IV injection (Pharmacokinetic Analysis) | | Result: | The CL, Vss, T1/2, AUC0-t, and AUC0-∞ values of 42.4 mL/min/kg, 4.06 L/kg, 2.42 hours, 386 ng/h/mL, and 405 ng/h/mL, respectively.
|
| [IC 50]
NEK2: 3 nM (IC50) | [References]
[1] Xi JB, et al. Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities. Eur J Med Chem. 2017 Jan 27;126:1083-1106. DOI:10.1016/j.ejmech.2016.12.026 |
|
|